National Centre For Pharmacoeconomics

Aidan Lyncht HSE should not be expected to pay for drugs that are not innovative

Number of indications covered by VHI initiative now 13, not three as had been thought

Move raises questions of equity between public and private patients

Consultant oncologist says inequity between public and private healthcare ‘very troubling’

Access to Medicines Ireland seeks change in R&D approach of pharmaceutical companies

Study examines access to 121 drugs approved since 2015 by EU regulator

Medicines generally blocked on basis of price as Ipha says delay ‘unacceptably long’

Spinraza is the latest in a series of controversial drugs that have put Ireland’s unique approval system in the spotlight

Cantillon: Patients have one shot at treatment but what if it is deemed too expensive?

Row between industry and body that advises the HSE over access to market for new medicines

Labour TD criticises selective provision of drug to women caught up in CervicalCheck controversy

‘It’s also important for researchers to hear what patients want from new drugs’

‘You have to ask why other countries have been happy with the clinical evidence but not here’ - mother of girl (10)

HSE representatives defend process for deciding which drugs to reimburse

Healthcare companies gave €30 million to hospitals, medical staff in 2016, says Minister

Kuvan is the only drug treatment for rare metabolic ‘heel prick test’ disorder